Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

Table 2 Patient experiences and satisfaction with antifibrotic treatment after three and six months in the overall group (n = 75)

	Month 3	Month 6	Difference (95% CI)	p-value
Satisfaction with effectiveness	1.6 (1.6)	1.6 (1.8)	0.0 (− 0.3–0.5)	0.70
Satisfaction with side-effects	1.8 (2.0)	1.6 (2.1)	0.2 (− 0.4–0.6)	0.57
Satisfaction with ease of use	2.9 (1.6)	2.7 (1.7)	0.2 (− 0.1–0.6)	0.18
Overall satisfaction with medication	2.1 (1.8)	2.1 (1.9)	0.0 (−0.4–0.5)	0.90
Experiences with effectiveness	2.0 (0.9)	2.0 (1.1)	0.0 (−0.4–0.5)	0.84
Experiences with side-effects	3.1 (1.1)	2.9 (1.2)	0.2 (−0.3–0.5)	0.44
Experiences with ease of use	3.9 (0.5)	3.8 (0.5)	0.1 (−0.1–0.2)	0.38
Number of reported side-effects per patient	6.4 (4.2)	5.8 (4.7)	0.6 (−0.2–1.4)	0.14
Severity score side-effects	9.5 (11.1)	8.7 (9.3)	0.8 (−1.6–3.2)	0.51

Data are presented as mean (SD). Experiences are scored on a scale from 0 to 4; a higher score corresponds with more positive experiences. Satisfaction is scored on a scale from − 5 to 5

ISSN: 1465-993X